Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer”
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference5 articles.
1. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma;O’Malley;Gynecol. Oncol.,2022
2. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials;Nitecki;Gynecol. Oncol.,2021
3. The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: lessons being learned and new questions emerging from phase 3 trial long-term outcome data;Matulonis;Gynecol. Oncol.,2022
4. PARP inhibitors and myeloid neoplasms: a double-edged sword;Csizmar;Cancers (Basel),2021
5. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian Cancer treated with Rucaparib;Kwan;JAMA Oncol.,2021
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms;ESMO Open;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3